Program
lysergide D-tartrate
Also written as “DT120” and “MM120”.
Its studies are mostly in Generalized Anxiety Disorder · Depressive Disorder, Major · Attention Deficit Disorder with Hyperactivity, led by Definium Therapeutics US.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Definium Therapeutics US | 64 open or running | phase 3since Dec 16, 2024 | Dec 21, 2021 | Sep 2027phase 3 · NCT07592689 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 21, 2021First study: phase 2 study in Attention Deficit Disorder with HyperactivityFirst studyNCT05200936 · 53 enrolled · Netherlands, Switzerland
- May 27, 2022Phase 2 study in Generalized Anxiety DisorderNCT05407064 · 198 enrolled · United States
- Dec 16, 2024Phase 3 study in Generalized Anxiety DisorderNCT06741228 · 214 enrolled · United States
- Jan 30, 2025Phase 3 study in Generalized Anxiety DisorderNCT06809595 · 245 enrolled · United States, Czechia, France and more
- Apr 16, 2025Phase 3 study in Depressive Disorder, MajorNCT06941844 · 149 enrolled · United States
- May 12, 2026Phase 3 study in Depressive Disorder, MajorNCT07592689 · 165 planned · United States
Ahead
- Sep 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT07592689
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07592689Depressive Disorder, Major · United States | 3 | Recruiting | Sep 2027 | 165 |
| NCT06941844Depressive Disorder, Major · United States | 3 | Active, not recruiting | May 20, 2026 | 149 |
| NCT06809595Generalized Anxiety Disorder · United States, Czechia, France and more | 3 | Active, not recruiting | Aug 13, 2026 | 245 |
| NCT06741228Generalized Anxiety Disorder · United States | 3 | Active, not recruiting | Jul 15, 2026 | 214 |
| NCT05407064Generalized Anxiety Disorder · United States | 2 | Completed | Oct 6, 2023 | 198 |
| NCT05200936Attention Deficit Disorder with Hyperactivity · Netherlands, Switzerland | 2 | Completed | Nov 6, 2023 | 53 |
How it is read
Names in the registry
- “DT120”, 4 entries
- “MM120”, 2 entries
Conditions, from the studies’ own filings
- Generalized Anxiety Disorder, 3 studies
- Depressive Disorder, Major, 2 studies
- Attention Deficit Disorder with Hyperactivity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.